Thursday, January 3, 2013
Astex Pharmaceuticals Inc., of Dublin, Calif., said it started a Phase II study testing SGI-110 in advanced hepatocellular carcinoma (HCC) patients who failed prior treatment with Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG).
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.